Open AccessDapagliflozin: an effective adjunctive treatment in type 1 diabetes
Author(s) -
Ghasem Yadegarfar,
Mark Livingston,
Gabriela Cortes,
Ramadan Alshames,
Kate Leivesley,
Ann Metters,
Linda Horne,
Tom Steele,
Adrian Heald
Publication year - 2021
Publication title -
cardiovascular endocrinology and metabolism
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2574-0954
DOI - 10.1097/xce.0000000000000248
Subject(s) - dapagliflozin , medicine , hypoglycemia , type 1 diabetes , type 2 diabetes , diabetes mellitus , bolus (digestion) , basal (medicine) , insulin , adjunctive treatment , endocrinology
Many people with type 1 diabetes (T1DM) continue to run high HbA1c levels with an associated elevated risk of cardiovascular events and increased mortality. We describe here how adjunctive prescription of an SGLT2 inhibitor has improved the glycaemic control of several people with T1DM, where the new technology has been intensively deployed.